A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB004, a CTLA-4-Ig Fusion Protein Designed for Increased Binding Affinity and Extended Half-life, in Healthy Volunteers

被引：0

作者：

Sellwood, Cory ^{[1
]}

Gao, Minggeng ^{[2
]}

Zhang, Sheen ^{[2
]}

Matijevic, Mark ^{[2
]}

Wax, Stephen ^{[3
]}

Yamashita, Mason ^{[2
]}

Yu, Shan ^{[2
]}

Arora, Sujata ^{[2
]}

Kirk, Rachel ^{[2
]}

机构：

[1] New Zealand Clin Res, Christchurch, New Zealand

[2] Zenas Biopharma, Waltham, MA USA

[3] Zenas Biopharma, Newton, MA USA

来源：

ARTHRITIS & RHEUMATOLOGY | 2024年 / 76卷

关键词：

NEONATAL FC-RECEPTOR;

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

2254

引用

页码：4535 / 4536

页数：2

共 5 条

[1] A Phase 1 Single Ascending Dose Study to Evaluate the Safety and Pharmacokinetics of ZB002, an Anti-TNFα mAb Designed for Extended Half-life, in Healthy Volunteers
Sellwood, Cory
Gao, Minggeng
Matijevic, Mark
Wax, Stephen
Yamashita, Mason
Yu, Shan
Arora, Sujata
Kirk, Rachel
ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 4534 - 4535
[2] A PHASE 1 SINGLE ASCENDING DOSE STUDY EVALUATING THE SAFETY, TOLERABILITY, AND PHARMACODYNAMIC EFFECTS OF MDK-703, AN IL-7 MIMETIC WITH EXTENDED HALF-LIFE
Friend, Richard
Baxter, Bryan
Park, Inkyung Angie
Cwirla, Steven
Barrett, Ronald
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A657 - A657
[3] EVALUATION OF THE SINGLE DOSE PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY OF GS-3583, A FLT3 AGONIST FC FUSION PROTEIN, IN A PHASE 1 STUDY IN HEALTHY VOLUNTEERS.
Dauki, A.
Rajakumaraswamy, N.
Trowe, T.
Singh, I.
Vashishtha, A.
Weng, W.
Kuhne, M.
Qin, A.
Schwabe, C.
Othman, A.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2022, 111 : S18 - S18
[4] A phase 1, single and fractionated, ascending dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietic mimetic antibody fusion protein, CNT0528, in healthy male subjects
Franson, KL
Burggraaf, J
Bouman-Trio, EA
Cohen, AF
Miller, BE
Jang, H
Marciniak, SJ
van de Ketterij, EPS
Frederick, B
Jiao, Q
Getsy, J
Bald, EH
Walker, H
Schantz, A
Ford, JA
Mascioli, K
Kowalchick, JB
BLOOD, 2005, 106 (11) : 151B - 151B
[5] A phase 1, single ascending dose study evaluating the safety, pharmacokinetics and pharmacodynamics of subcutaneous administration of an erythropoeitic mimetic antibody fusion protein (CNTO 528) in healthy male subjects.
Bouman-Thio, E.
Franson, K.
Burggraaf, J.
Cohen, A.
Miller, B.
Bai, S.
Marcimak, S.
Yohrling, J.
Jiao, T.
Shankar, G.
Ramani, K.
Marini, J. C.
Pendley, C.
Ford, J.
Kowalchick, J.
Bald, E.
Frigo, M.
Frederick, B.
Walker, H.
Schantz, A.
Getsy, J.
Davis, H.
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2007, 81 : S95 - S95

← 1 →